NewsSource: EClinCloud

Livestream Preview | CDE Issues Three Patient-Centered Clinical Trial Guidelines

2 min readEClinCloud Editorial Team
Article image

Source: EClinCloud.


On July 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) issued and implemented 3 guidelines to advance the practical application of the "patient-centered" concept in drug development. According to the guidelines, patient-centered clinical trial conduct emphasizes the patient experience during implementation, enhancing convenience and reducing the burden for patients participating in clinical trials within a compliant and feasible scope, and conducting trials that are more patient-accessible, patient-friendly, and closely aligned with real-world clinical practice settings.

EClinCloud's product technologies and solutions consistently practice the "patient-centered" philosophy, placing patients at the center of data collection. EClinCloud eCOA is a key element in enabling patient-centered remote clinical trials; by collecting and processing assessment data from subjects and clinicians in a more efficient and convenient manner, it can not only improve subject compliance and better collect subject data, but also rapidly advance clinical trial conduct.

September 7, 2023, 19:00–20:00, join EClinCloud in the CMAC livestream room. Focusing on the topic "CDE's Trio of Patient-Centered Guidelines", EClinCloud Co-Founder and Chief Business Officer Su Quanyu will join the thematic discussion from a frontline perspective and share further insights with industry peers.
Article image

Scan the QR code in the poster below to register for the livestream.

Article image




About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interconnected all-in-one clinical trial cloud platform (covering technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, and solutions within them including scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). Combining cutting-edge technology with life data, EClinCloud is building a globally leading "patient-centered" SaaS cloud platform supporting clinical evidence to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs/devices, and benefit countless patients.




Article image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.